ACRS - Aclaris +19% after positive results from wart study October, 24 2019 07:12 PM Aclaris Therapeutics Inc. Aclaris (NASDAQ:ACRS) has vaulted 19.1% after its postmarket news that its topical wart drug met its goal in a late-stage trial.More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...